WO2014163413A1 - 인삼열매 추출물을 포함하는 수명 연장용 조성물 - Google Patents
인삼열매 추출물을 포함하는 수명 연장용 조성물 Download PDFInfo
- Publication number
- WO2014163413A1 WO2014163413A1 PCT/KR2014/002886 KR2014002886W WO2014163413A1 WO 2014163413 A1 WO2014163413 A1 WO 2014163413A1 KR 2014002886 W KR2014002886 W KR 2014002886W WO 2014163413 A1 WO2014163413 A1 WO 2014163413A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- ginseng
- extract
- ginseng fruit
- less
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a composition for extending the life, and more particularly to a composition for extending the life comprising the extract of ginseng fruit.
- the present invention provides a composition for extending the life comprising the ginseng fruit extract as an active ingredient to achieve the above object.
- the present invention can include the ginseng fruit extract as an active ingredient to extend the life of the individual, medical value is high. Specifically, it was confirmed that the ginseng fruit extract of the present invention as an active ingredient of the composition of the present invention can lower their mortality and extend their lifespan in fruit flies and worms having high genetic homology with humans. In addition, in the present invention, ginseng fruit extract as an active ingredient of the composition of the present invention can reduce the number of specific cells known in the art as aging markers (Mechanisms of Ageing and Development (2004), 125; 381-390). Since it was revealed in the mouse, it was confirmed that the composition of the present invention can enable to extend the life of the mammal.
- 1 is a graph showing the life curve of fruit flies fed ginseng fruit extract.
- Figure 2 is a graph showing the average life span of nematode fed ginseng fruit extract.
- extended life means prolonging the life of an individual over a longer period than natural cases.
- the term “extension of life” may mean prolonging the life span of an individual determined by innate or acquired factors such as genetic factors.
- the “extension of life” may be to extend the life of the individual by appropriately controlling the factors that control the lifespan caused by genetic factors of the individual, such as the expression level of related genes, the generation of related proteins, Prolonging the life of an individual by appropriately controlling life control factors caused by acquired factors, and the like.
- the prolongation of life may be to prolong the natural time of death of the organism.
- the "ginseng” may be so-called Korean ginseng, and may be Panax ginseng CA Meyer.
- the "ginseng fruit” is to include both the organism of the ginseng fruit and ginseng fruit dried.
- the acquisition time of “ginseng fruit” is very limited, it is obvious to those skilled in the art that the composition of dried ginseng fruit and the composition of dried ginseng fruit are the same, since the obtained ginseng fruit is dried to promote storage. .
- the "ginseng fruit extract” may include without limitation any material obtained by treating ginseng fruit by an extraction method known in the art.
- the "extract” may include all extracts obtained by using ginseng fruit, regardless of the extraction method, extraction solvent, extracted component or form of the extract. It includes a broad concept that includes all of the materials that can be obtained by processing or processing the fruit extract in different ways, more specifically, the processing or processing may be further fermentation or enzymatic treatment for the ginseng fruit extract It is not limited.
- the "ginseng fruit extract” in the present specification may be a primary extract obtained by adding a solvent to the organism or dried fruit of ginseng fruit (g).
- the ginseng fruit may be separated from the seed and include only the flesh and skin of the ginseng fruit.
- the ginseng fruit dried herein is not limited if it is to dry the ginseng fruit through a drying method known in the art, specifically, may be daylight drying, hot air drying, evaporation drying, spray drying, or freeze drying, but is not limited thereto. no.
- the solvent may be water or a lower alcohol of C 1 to C 6 , or may be one or more from the group consisting of acetone, ether, ethyl acetate, diethyl ether, ethyl methyl ketone, and chloroform.
- the solvent may be ethanol, but is not limited thereto.
- the primary extract may also include a secondary extract obtained by adding the solvent to the biological or ginseng fruit dried (a ') of ginseng fruit, and filtering it and concentrating under reduced pressure.
- concentration under reduced pressure is not limited as long as it is known in the art.
- the "ginseng fruit extract” may also be a tertiary extract obtained by removing a fat-soluble component from the primary extract or the secondary extract.
- the removal of the fat-soluble component may be used without limitation as long as it is known in the art, and specifically, ether may be treated but is not limited thereto.
- the "ginseng fruit extract” may be a quaternary extract obtained by extracting the tertiary extract with a lower alcohol of C1 to C5.
- the alcohol may include methanol, ethanol or butanol.
- the extract of the ginseng fruit bar is composed of ginseng and other compositions and content, for example, the ratio of PT (Protopanaxatriol) ginsenoside to PD (Protopanaxadiol) ginsenoside may be 0.5 to 2.5. This ratio is not found at all in the known ginseng root extract. That is, the ginseng fruit has a higher ginsenoid content than ginseng, and is a "ginsenoside Rb1, Rb2, Rc and Rd", which are PT (Protopanaxatriol) -based ginsenoids, and a "ginsenoside Re, which is a PD (Protopanaxadiol) -based ginsenoid.
- the ratio of Protopanaxadiol (PD) based ginsenoside to PT (Protopanaxatriol) based ginsenoside may be 0.5 or more, 0.55 or more, 0.6 or more, 0.65 or more, 0.69 or more, 0.7 or more, 0.73 or more.
- the extract of the ginseng fruit includes one or more rich minerals selected from the group consisting of potassium, calcium, iron, phosphorus, magnesium and zinc, and / or vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin C, vitamin E,
- rich minerals selected from the group consisting of potassium, calcium, iron, phosphorus, magnesium and zinc
- vitamin A vitamin B1, vitamin B2, vitamin B6, vitamin C, vitamin E
- One or more abundant vitamins selected from the group consisting of vitamin K, vitamin B3 (niacin), vitamin B5 (pantothenic acid) and vitamin B9 (folic acid) may be included.
- vitamins selected from the group consisting of vitamin K, vitamin B3 (niacin), vitamin B5 (pantothenic acid) and vitamin B9 (folic acid) may be included.
- the present invention relates to a composition for extending the life of a ginseng fruit extract in one aspect.
- the composition may comprise from 0.001% to 80% by weight of ginseng fruit extract based on the total weight of the composition.
- ginseng fruit extract When included in the above range is not only suitable for showing the intended effect of the present invention, it can satisfy both the stability and safety of the composition, it may be appropriate to use in the above range in terms of cost-effectiveness. Specifically, when the ginseng fruit extract is less than 1% by weight, sufficient life extension effect may not be obtained, and when it exceeds 80% by weight, safety and formulation stability may be lowered.
- the composition of one aspect of the present invention may comprise 5% to 60% by weight or 10% to 30% by weight of ginseng fruit extract based on the total weight of the composition.
- the composition may have a ratio of Protopanaxadiol (PD) based ginsenoside to PT (Protopanaxatriol) based ginsenoside may be 0.5 to 2.5. This ratio is not found at all in the known ginseng root extract. That is, the ginseng fruit has a higher ginsenoid content than ginseng, and is a "ginsenoside Rb1, Rb2, Rc and Rd", which are PT (Protopanaxatriol) -based ginsenoids, and a "ginsenoside Re, which is a PD (Protopanaxadiol) -based ginsenoid.
- PD Protopanaxadiol
- PT Protopanaxatriol
- the ratio of Protopanaxadiol (PD) based ginsenoside to PT (Protopanaxatriol) based ginsenoside may be 0.5 or more, 0.55 or more, 0.6 or more, 0.65 or more, 0.69 or more, 0.7 or more, 0.73 or more.
- the composition may be a food composition.
- the food composition according to another aspect of the present invention includes a favorite food or health food composition.
- the formulation of the food composition is not particularly limited, but may be, for example, formulated into a liquid such as tablets, granules, powders, drinks, caramels, gels, bars, and the like.
- the food composition of each formulation may be suitably selected by those skilled in the art according to the formulation or purpose of use in addition to the active ingredient, and may be combined with other raw materials, and synergistic effects may occur when applied at the same time.
- Dosage determination of the active ingredient is within the level of one of skill in the art, and its daily dosage may be, for example, 0.1 ⁇ g / kg / day to 5000 ⁇ g / kg / day, more specifically 50 ⁇ g / kg / day to 500 ⁇ g. / kg / day, but is not limited thereto, and may vary depending on various factors such as age, health condition, and complications of the subject to be administered.
- the composition may be a pharmaceutical composition.
- composition according to one aspect of the present invention may be administered orally, parenteral, rectal, topical, transdermal, intravenous, intramuscular, intraperitoneal, subcutaneous.
- Formulations for oral administration may be, but are not limited to, tablets, pills, soft and hard capsules, granules, powders, granules, solutions, emulsions or pellets. These formulations may contain, in addition to the active ingredient, diluents (e.g. lactose, dextrose, sucrose, mannitol, sorbitol, cellulose or glycine), glidants (e.g. silica, talc, stearic acid or polyethylene glycol), or binders (e.g. magnesium aluminum Silicates, starch pastes, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose or polyvinylpyrrolidine). It may optionally contain pharmaceutical additives such as disintegrants, absorbents, colorants, flavors, or sweeteners.
- the tablets can be prepared by conventional mixing, granulating or coating methods.
- Formulations for parenteral administration may be, but are not limited to, eye drops, injections, drops, lotions, ointments, gels, creams, suspensions, emulsions, suppositories, patches or sprays.
- the active ingredient of the pharmaceutical composition according to one aspect of the present invention will vary depending on the age, sex, weight, pathology and severity of the subject to be administered, the route of administration or the judgment of the prescriber. Dosage determination based on these factors is within the level of one skilled in the art and its daily dosage may be, for example, 0.1 ⁇ g / kg / day to 100 ⁇ g / kg / day, more specifically 5 ⁇ g / kg / day to 50 ⁇ g / kg / day, but is not limited thereto.
- the present invention may relate to the use of ginseng fruit extract in the preparation of a composition for extending life.
- the use includes both therapeutic or non-therapeutic uses.
- the present invention may relate to a method of administering ginseng fruit extract to an individual for prolonging lifespan.
- Ginseng fruit pretreatment Raw ginseng (Panax ginseng C.A. Meyer) fruit was harvested to separate and removed seeds, and then the flesh and skin of ginseng fruit were prepared by sunlight drying or hot air drying.
- Raw ginseng (Panax ginseng C.A. Meyer) fruit was harvested, seed was separated and removed, and then ginseng fruit raw material was prepared by mixing the fruit juice, pulp, and rind of ginseng fruit. 3L of ethanol was added to 1 kg of the ginseng fruit material thus prepared, and the mixture was extracted under reflux at 70 ° C. for 4 hours, filtered, and concentrated under reduced pressure at 45 ° C. to obtain 30 g of fresh fruit extract of ginseng.
- Ginseng Root Extract 300 g was obtained.
- Example 1 Example 2 Comparative Example 1 Total Saponin Content (Dry Weight) 33.42% 31.08 16.70% PD / PT ratio 0.73 0.69 3.23
- the ginseng fruit extract prepared in Example 1 was confirmed to have a content more than twice the total saponin of the ginseng root extract prepared in Comparative Example 1 in the total saponin (total ginsenoside) content.
- ginseng fruit extract also includes the raw ginseng fruit extract. It is true.
- the ratio of PD (Protopanaxadiol)-"ginsenosides Rb1, Rb2, Rc and Rd” and PT (Protopanaxatriol)-"ginsenosides Re, Rg1 and Rg2" (PD / PT ratio ) Showed a significant difference between the ginseng fruit extract prepared in Example 1 and the ginseng root extract prepared in Comparative Example 1.
- the total saponin content of the ginseng fruit extract prepared in Example 1 and the raw ginseng fruit extract prepared in Example 2 is almost no difference, it is apparent to those skilled in the art that the ginseng fruit extract of the present invention also includes raw ginseng fruit extract. One is true.
- Example 2 Potassium (mg / 100g) 5865.57 4977.50 Magnesium (mg / 100g) 354.38 297.54 Calcium (mg / 100g) 819.26 914.22 Zinc (mg / 100g) 178.49 201.25 Iron (mg / 100g) 59.31 52.11 Vit.A (ug / 100g, RE) 213.11 145.85 Phosphorus (mg / 100g) 187.17 156.95 Vit.B1 (mg / 100g) 12.29 10.09 Vit.B2 (mg / 100g) 8.45 5.05 Vit.B6 (mg / 100g) 10.50 15.44 Vit.C (mg / 100g) 4.91 7.13 Vit.E (mg / 100g, ⁇ -TE) 23.61 31.25 Vit.K ( ⁇ / 100g) 232.12 129.82 Niacin (mg / 100g)
- the extract obtained from the dried ginseng fruit dry of the present invention and the extract of raw ginseng fruit was confirmed that the properties are almost the same.
- Wild-type fruit flies (Oregon-R, Canton-S, Bloomington Drosophila Stock Center (BDSC, Bloomington, Ind.)) Were grown from bottles containing 10% Sucrose-10% Yeast (SY) food to adults.
- the breeding room was kept at 25 ° C, 50% humidity, and kept 12 hours of light and 12 hours of dark.
- SY medium (10% sugar, 10% dry yeast, 0.8% agar, antifungal 0.5%, anti-mite 110 ⁇ l / 100ml) was prepared. Each ginseng fruit extract sample having a concentration of 10 or 25 mg / ml was added to 10% SY medium cooled to 60 ° C., cooled, and then hardened. The medium thus prepared was stored at 4 ° C. and used within two weeks.
- the ginseng fruit extract having a concentration of 0 (control), 10 and 25 ⁇ g / ml and the ginseng root extract of 25 ⁇ g / ml were ingested into wild type (OregonR, OR) fruit flies, and their lifespan was measured.
- Adult fruit flies were collected in a cohort for 48 hours, and 100 female and male fruit flies were placed in cages, and the dead fruit flies were removed and recorded every two days with fresh medium. Experiments were performed until all the fruit flies in the cage died. A total of 300 animals were set up, 3 cages per concentration.
- the results of FIG. 1 were obtained using Kaplan-Meier (product-linit) and log rank (generalized Savage, Mantel-Cox) test statistical analysis.
- NVM Nematode growth medium
- Wild nematodes were distributed at the Caenorhabditis Genetic center (University of Minnesota, St. Paul, MN, USA). Selected eggs were incubated for 16 hours at 20 C in NGM plates added with S-basal buffer (100 mM NaCl, 0.01 mM cholesterol, 50 mM potassium phosphate, pH 6.0). Hatched eggs (L1-stage larvae) were transferred to an NGM plate containing Escherichia coli strain OP50 as a food source and raised to L4 larvae.
- S-basal medium supplemented with 3 mM CaCl2, 3mM MgSO4, 50mM EDTA, 25mM FeSO4, 10 mM MnCl2, 10 mM L4 larvae containing 10 mg / ml ginseng fruit extract and 10 mg / ml ginseng root extract ZnSO 4, 1 mM CuSO 4, and 10 mM KH 2 PO 4 (pH 6.0), E. coli OP50] and incubated. A total of 90 animals were set up. The medium was changed every other day to determine the number of surviving nymphs.
- T-Cell subsets ie the number of CD4 and CD8 memory cells
- the distribution of T-Cell subsets is used as an aging marker in mammals, including humans, and thus is widely used as an indicator for predicting the lifespan of individuals (Mechanisms of Ageing and Development (2004). , 125; 381-390).
- the number of CD4 memory cells increases as aging progresses, and as the number of cells increases, the number of CD4 memory cells dies quickly regardless of the presence or absence of a disease in the individual (FASEB J. (1997) 11). , 775-783).
- mice Central Laboratory Animal, Korea
- All subjects were housed in individual cages, so that food and water were ingested freely, the temperature was maintained at 22 ⁇ 1 ° C, 60 ⁇ 5% humidity, and the contrast was changed every 12 hours.
- the diet was fed with a normal chow diet (D12450B, Research Diets, New Brunswick, NJ, USA). The health status was checked by measuring feed intake and weight weekly. Ginseng fruit extract was orally administered to each mouse (10 per group) for 6 months at 50 mg / kg and 100 mg / kg daily. The control group used mice that provided only a normal diet for 6 months.
- Vitamin B12 ......... 0.2 ⁇ g
- Nicotinic Acid Amide ... 1.7 mg
- composition ratio of the said vitamin and mineral mixture was mixed and consisted with the component suitable for a healthy food in a preferable Example, the compounding ratio may be arbitrarily modified.
- the above ingredients are mixed according to a conventional method for preparing a healthy beverage, then stirred and heated at 85 ° C. for about 1 hour, and then the resulting solution is filtered and sterilized.
- ginseng fruit extract 100 mg of ginseng fruit extract, 50 mg of soybean extract, 100 mg of glucose, 50 mg of red ginseng extract, 96 mg of starch and 4 mg of magnesium stearate were mixed and 40 mg of 30% ethanol was added to form granules and dried at 60 ° C. And tableting using a tableting machine.
- ginseng fruit extract 100 mg of ginseng fruit extract, 50 mg of soybean extract, 100 mg of glucose and 600 mg of starch are mixed, and 100 mg of 30% ethanol is added to form granules, followed by drying at 60 ° C. to form granules and then filling into fabric.
- the present invention relates to a composition for extending the life, and more particularly to a composition for extending the life comprising the extract of ginseng fruit.
- the present invention can include the ginseng fruit extract as an active ingredient to extend the life of the individual, medical value is high.
- the ginseng fruit extract which is an active ingredient of the composition of the present invention, can reduce the number of specific cells known as aging markers in the art (Mechanisms of Ageing and Development (2004), 125; 381-390). Since it was found in the present invention that the composition of the present invention can enable to extend the life of the mammal, the medical value is very high.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
실시예 1 | 실시예 2 | 비교예 1 | |
토탈사포닌 함량(건조중량) | 33.42% | 31.08 | 16.70% |
PD/PT 비율 | 0.73 | 0.69 | 3.23 |
성분 | 실시예 1 | 실시예 2 | 성분 | 실시예 1 | 실시예 2 |
칼륨(mg/100g) | 5865.57 | 4977.50 | 마그네슘(mg/100g) | 354.38 | 297.54 |
칼슘(mg/100g) | 819.26 | 914.22 | 아연(mg/100g) | 178.49 | 201.25 |
철(mg/100g) | 59.31 | 52.11 | Vit.A(ug/100g, RE ) | 213.11 | 145.85 |
인(mg/100g) | 187.17 | 156.95 | Vit.B1(mg/100g) | 12.29 | 10.09 |
Vit.B2(mg/100g) | 8.45 | 5.05 | Vit.B6(mg/100g) | 10.50 | 15.44 |
Vit.C(mg/100g) | 4.91 | 7.13 | Vit.E(mg/100g, α-TE) | 23.61 | 31.25 |
Vit.K(㎍/100g) | 232.12 | 129.82 | 나이아신(mg/100g, NE) | 5.76 | 2.01 |
판토텐산(mg/100g) | 5.87 | 6.15 | 엽산(㎍/100g) | 349.97 | 423.35 |
Subset | 대조군 | 인삼열매 추출물 50mg/kg/day | 인삼열매 추출물 100mg/kg/day |
CD4M | 38.6±11.4 | 33.4±5.4 | 30.1±6.8 |
CD8M | 55.6±15.1 | 50.4±9.2 | 47.3±4.8 |
Claims (5)
- 인삼 열매의 추출물을 유효성분으로 포함하는 수명 연장용 조성물.
- 청구항 제1항에 있어서,상기 조성물은 조성물 총중량에 대하여 0.001 중량% 내지 80 중량%의 인삼열매 추출물을 포함하는, 수명 연장용 조성물.
- 청구항 제1항에 있어서,상기 인삼 열매의 추출물은 PT(Protopanaxatriol)계 진세노사이드에 대한 PD(Protopanaxadiol)계 진세노사이드의 비율이 0.5 내지 2.5인, 수명 연장용 조성물.
- 제1항 또는 제2항에 있어서,상기 조성물은 약학 조성물인, 수명 연장용 조성물.
- 제1항 또는 제2항에 있어서,상기 조성물은 건강식품 조성물인, 수명 연장용 조성물.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/781,160 US20160051606A1 (en) | 2013-04-03 | 2014-04-03 | Composition for life extension containing ginseng fruit extract |
JP2016506242A JP6436971B2 (ja) | 2013-04-03 | 2014-04-03 | 朝鮮人参の実抽出物を含む、CD4及びCD8 memory cell減少用の組成物 |
CN201480019504.6A CN105101983A (zh) | 2013-04-03 | 2014-04-03 | 包含人参浆果提取物的用于寿命延长的组合物 |
HK15112311.0A HK1211482A1 (en) | 2013-04-03 | 2015-12-15 | Composition for life extension containing ginseng berry extract |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2013-0036393 | 2013-04-03 | ||
KR20130036393 | 2013-04-03 | ||
KR10-2014-0038804 | 2014-04-01 | ||
KR1020140038804A KR102249706B1 (ko) | 2013-04-03 | 2014-04-01 | 인삼열매 추출물을 포함하는 수명 연장용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014163413A1 true WO2014163413A1 (ko) | 2014-10-09 |
Family
ID=51658634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/002886 WO2014163413A1 (ko) | 2013-04-03 | 2014-04-03 | 인삼열매 추출물을 포함하는 수명 연장용 조성물 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014163413A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112999167A (zh) * | 2021-03-01 | 2021-06-22 | 深圳前海九华国际投资控股有限公司 | 人参子速释微丸及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090033775A (ko) * | 2007-10-01 | 2009-04-06 | 김동청 | 인삼의 헥산 추출물을 유효성분으로 하는 면역증강 효과를가진 조성물 |
-
2014
- 2014-04-03 WO PCT/KR2014/002886 patent/WO2014163413A1/ko active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090033775A (ko) * | 2007-10-01 | 2009-04-06 | 김동청 | 인삼의 헥산 추출물을 유효성분으로 하는 면역증강 효과를가진 조성물 |
Non-Patent Citations (4)
Title |
---|
ATTELE, A. S. ET AL.: "Antidiabetic effects of Panax ginseng berry extract and the identification of an effective component", DIABETES, vol. 51, 2002, pages 1851 - 1858 * |
LEE, J.-H. ET AL.: "Study on life span extension efficacy by Korean red ginseng", JOURNAL OF GINSENG RESEARCH, vol. 31, no. 4, 2007, pages 210 - 216 * |
LEE, S. Y. ET AL.: "Chemical constituents and biological activities of the berry of Panax ginseng", JOURNAL OF MEDICINAL PLANTS RESEARCH, vol. 4, no. 5, 2010, pages 349 - 353 * |
MASSIE, H. R. ET AL.: "Effect of ginseng on the life span of Drosophila", AGE, vol. 7, 1984, pages 17 - 18 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112999167A (zh) * | 2021-03-01 | 2021-06-22 | 深圳前海九华国际投资控股有限公司 | 人参子速释微丸及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Melliou et al. | Chemistry and bioactivities of royal jelly | |
WO2010058926A2 (ko) | 생강 추출물 또는 쇼가올을 포함하는 약학 조성물 | |
WO2020091166A1 (ko) | 신규 유산균 및 이의 용도 | |
WO2015002393A1 (ko) | 감귤 미성숙과 추출물, 또는 시네프린 또는 이의 염을 유효성분으로 포함하는 염증성 피부질환 치료 또는 예방용 조성물 | |
WO2021132879A1 (ko) | 한국인 영유아 유래 신규한 비피도박테리움 애니멀리스 락티스 lm1017을 유효성분으로 포함하는, 아토피 피부염의 예방 및 치료용 조성물 | |
WO2015002391A1 (ko) | 월경 전기 증후군 및 월경통 완화의 기능을 갖는 조성물 | |
WO2015005630A1 (ko) | Tslp 분비 저해능 및 알러지성 질환의 개선능을 가지는 조성물 | |
WO2020040432A1 (ko) | 인삼열매 추출물을 유효성분으로 함유하는 근육 질환의 예방 또는 치료용 약학적 조성물 | |
WO2017073849A1 (ko) | 톱니모자반 추출물을 유효성분으로 포함하는 관절염 예방 또는 치료용 조성물 | |
WO2016190566A2 (ko) | 아위버섯 물 추출물을 유효성분으로 함유하는 대사성질환의 예방 및 치료용 약학적 조성물 또는 건강기능성식품 | |
WO2020209690A1 (ko) | 가래나무 추출물, 분획물 또는 그 유래 생리활성 물질을 유효성분으로 함유하는 최종당화산물 생성 억제 및 분해 효과를 가지는 약학적 조성물 | |
WO2014163413A1 (ko) | 인삼열매 추출물을 포함하는 수명 연장용 조성물 | |
WO2023140657A1 (ko) | 간이식환자 장내균총 분석과 이를 통한 이식상태 모니터링과 면역조절 테라그노시스 조성물 | |
WO2016093613A2 (ko) | 진피 추출물을 포함하는 이상 체중 감소 증상의 예방 또는 치료용 조성물 | |
WO2018008973A1 (ko) | 연교 추출물을 유효성분으로 함유하는 말초신경병증 예방, 개선 또는 치료용 조성물 | |
WO2021040416A1 (ko) | 비쑥 추출물을 유효성분으로 포함하는 골대사성 질환으로 유발된 골소실 예방 또는 치료용 약제학적 조성물 | |
WO2015167240A1 (ko) | 알피나 골무꽃 추출물을 포함하는 조성물 | |
WO2018080158A1 (ko) | 좁은잎보리장나무 추출물을 유효성분으로 함유하는 인지기능 장애의 예방, 개선 또는 치료용 조성물 | |
WO2018030838A1 (ko) | 락토바실러스 인테스티날리스를 포함하는 갱년기 예방 또는 치료용 조성물 | |
WO2023229263A1 (ko) | 락토바실러스 플란타룸 nchbl-004 균주 또는 이의 배양액을 포함하는 대사성 질환 예방, 치료 또는 개선용 조성물 | |
WO2017048051A1 (ko) | 인지기능장애 또는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물 | |
WO2018056676A1 (ko) | 퍼플콘 추출물을 함유하는 피부 질환의 예방 또는 치료용 약제학적 조성물 | |
WO2022145711A1 (ko) | 마이크로코커스 루테우스 유래 세포외 소포를 포함하는 대사질환 예방 또는 치료용 조성물 | |
WO2023128197A1 (ko) | 우도 땅콩 새싹 추출물을 유효성분으로 함유하는 근감소증의 개선, 예방 또는 치료용 조성물 | |
WO2024122768A1 (ko) | 복령 추출물을 포함하는 불면증 예방 또는 개선용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480019504.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14779763 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016506242 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14781160 Country of ref document: US |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 25.01.2016) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14779763 Country of ref document: EP Kind code of ref document: A1 |